Vertex Pharmaceuticals, Inc. (VRTX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Reshma Kewalramani
Employees:
4,800
50 NORTHERN AVENUE, BOSTON, MA 02210
6173416393

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.

Data derived from most recent annual or quarterly report
Market Cap 90.316 Billion Shares Outstanding257.552 Million Avg 30-day Volume 906.264 Thousand
P/E Ratio27.2333 Dividend Yield0.0 EPS3.55
Price to Revenue9.641 Debt to Equity0.0 EBITDA4.11 Billion
Price to Book Value5.9235 Operating Margin41.7212 Enterprise Value79.044 Billion
Current Ratio4.139 EPS Growth0.048 Quick Ratio3.816
1 Yr BETA 0.5341 52-week High/Low 367.0 / 276.57 Profit Margin35.4014
Operating Cash Flow Growth1.2443 Free Cash Flow to Firm (FCFF) TTM 2.902 Billion Free Cash Flow to Equity (FCFE) TTM2.905 Billion
Altman Z-Score13.5579
Earnings Report2023-10-26
View SEC Filings from VRTX instead.

View recent insider trading info

Vertex Pharmaceuticals, Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding VRTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding VRTX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-09-21 by BOZIC CARMEN
  • 4: filed on 2023-09-07 by BOZIC CARMEN
  • 3: filed on 2023-09-05 by ATKINSON EDWARD MORROW III
  • 4: filed on 2023-08-25 by TATSIS OURANIA
  • 4: filed on 2023-08-14 by KEARNEY TERRENCE C
  • 4: filed on 2023-08-14 by TATSIS OURANIA
  • 4: filed on 2023-08-14 by SACHDEV AMIT
  • 4: filed on 2023-08-11 by ALTSHULER DAVID
  • 4: filed on 2023-08-11 by BHATIA SANGEETA N.
  • 4: filed on 2023-07-18 by SACHS BRUCE I

    • Events (8k)

  • 8-K: filed on 2023-08-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-18:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-11:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-05:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
  • 8-K: filed on 2022-05-23:
    Item 8.01: Other Events
  • 8-K: filed on 2022-05-18:
    Item 5.07: Submission of Matters to a Vote of Security Holders

    • Proposed Sales (Form 144)

  • 144: filed on 2023-05-08:
  • 144: filed on 2023-05-05:
  • 144: filed on 2023-05-05:
  • 144: filed on 2023-05-03:
  • 144: filed on 2023-05-03:
  • 144: filed on 2023-05-02:
  • 144: filed on 2023-05-02:
  • 144: filed on 2023-05-02:
  • 144: filed on 2023-04-27:
  • 144: filed on 2023-04-12:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    39.9 Thousand total shares from 8 transactions

    Exercise Derivative Conversion (M)

    10 Thousand total shares from 1 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BOZIC CARMEN EVP AND CMO

    • Officer
    		 51,905 2023-09-19 6

    ATKINSON EDWARD MORROW III EVP, CHIEF TECHNICAL OPS. OFF.

    • Officer
    		 13,879 2023-08-29 1

    TATSIS OURANIA EVP, CHIEF REG. & QUALITY OFF.

    • Officer
    		 48,637 2023-08-23 7

    KEARNEY TERRENCE C

    • Director
    		 6,536 2023-08-10 2

    SACHDEV AMIT EVP, CHIEF PATIENT OFFICER

    • Officer
    		 66,261 2023-08-10 5

    ALTSHULER DAVID EVP, GLOBAL RESEARCH AND CSO

    • Officer
    		 32,038 2023-08-09 9

    BHATIA SANGEETA N.

    • Director
    		 4,386 2023-08-09 3

    KEWALRAMANI RESHMA CEO & PRESIDENT

    • Officer
    • Director
    		 118,906 2023-07-17 7

    SACHS BRUCE I

    • Director
    		 40,000 2023-07-14 7

    MCKENZIE DIANA

    • Director
    		 0 2023-07-14 5

    ARBUCKLE STUART A EVP, COO

    • Officer
    		 56,696 2023-06-15 9

    AMBROSE KRISTEN SVP & CHIEF ACCOUNTING OFFICER

    • Officer
    		 6,838 2023-05-30 4

    LEIDEN JEFFREY M EXECUTIVE CHAIRMAN

    • Officer
    • Director
    		 72,339 2023-05-05 5

    SANNA BASTIANO EVP, CELL & GENETIC THERAPIES

    • Officer
    		 32,038 2023-05-05 14

    CARNEY LLOYD

    • Director
    		 5,318 2023-05-01 2

    MCGLYNN MARGARET G

    • Director
    		 0 2023-05-01 1

    GARBER ALAN M

    • Director
    		 6,474 2023-05-01 1

    LEE YUCHUN

    • Director
    		 0 2023-05-01 5

    UPADHYAY SUKETU

    • Director
    		 2,726 2023-05-01 3

    WAGNER CHARLES F JR EVP & CHIEF FINANCIAL OFFICER

    • Officer
    		 49,611 2023-03-24 7

    BILLER JONATHAN EVP AND CHIEF LEGAL OFFICER

    • Officer
    		 11,587 2023-02-01 1

    LIU JOY SVP, GENERAL COUNSEL

    • Officer
    		 9,605 2022-08-15 0

    SILVA PAUL M SVP & CHIEF ACCOUNTING OFFICER

    • Officer
    		 22,719 2021-02-26 0

    PARINI MICHAEL EVP, CHIEF ADM, LEG & BD OFF

    • Officer
    		 30,837 2021-02-24 0

    YOUNG WILLIAM D

    • Director
    		 No longer subject to file 2020-06-01 0

    ULLIAN ELAINE

    • Director
    		 0 2019-06-01 0

    GRANEY THOMAS CHIEF FINANCIAL OFFICER

    • Officer
    		 12,430 2018-10-01 0

    SMITH IAN F EVP, COO

    • Officer
    		 52,005 2018-06-29 0

    CHODAKEWITZ JEFFREY EVP

    • Officer
    		 No longer subject to file 2018-04-01 0

    BOGER JOSHUA S

    • Director
    		 No longer subject to file 2017-06-08 0

    RILEY WAYNE JOSEPH

    • Director
    		 0 2015-06-01 0

    CONNOLLY THOMAS SVP, HUMAN RESOURCES

    • Officer
    		 34,525 2014-12-12 0

    HORTON KENNETH L EVP & CHIEF LEGAL OFFICER

    • Officer
    		 72,419 2014-11-17 0

    PACE MEGAN E SVP, CORP. COMMUNICATIONS

    • Officer
    		 43,350 2014-11-17 0

    MUELLER PETER EVP, GLOBAL R&D, CSO

    • Officer
    		 169,088 2014-06-16 0

    STAMOULIS CHRISTIANA SVP, CORP STRATEGY & BUS DEVLP

    • Officer
    		 0 2013-07-30 0

    KELLY LISA SVP, HUMAN RESOURCES

    • Officer
    		 27,347 2013-02-05 0

    EMMENS MATTHEW

    • Director
    		 0 2012-06-01 0

    WYSENSKI NANCY EVP, CHIEF COMMERCIAL OFFICER

    • Officer
    		 32,232 2012-05-14 0

    WINGER DENNIS L

    • Director
    		 6,500 2012-03-09 0

    HOWTON DAVID T SVP & CHIEF LEGAL OFFICER

    • Officer
    		 19,703 2012-02-02 0

    BOGER KENNETH S SVP & CHIEF LEGAL OFFICER

    • Officer
    		 292,187 2011-09-13 0

    CORDES EUGENE

    • Director
    		 12,000 2011-03-17 0

    SANDERS CHARLES A

    • Director
    		 0 2010-06-01 0

    COLLINSON STUART J

    • Director
    		 0 2010-06-01 0

    BRIMBLECOMBE ROGER W

    • Director
    		 0 2010-03-15 0

    GRAVES KURT EVP, CHIEF COMMERCIAL OFFICER

    • Officer
    		 60,485 2009-10-19 0

    GARRISON RICHARD C SVP AND CATALYST

    • Officer
    		 38,782 2009-05-18 0

    LEWIS-HALL FREDA C EVP, MEDICINES DEVELOPMENT

    • Officer
    		 53,334 2009-03-19 0

    BRANDT ERIC

    • Director
    		 0 2009-01-29 0

    ALAM JOHN J EVP, MED. DEV. GROUP & CMO

    • Officer
    		 141,932 2008-10-01 0

    POWER JOHANNA MESSINA VP & CONTROLLER

    • Officer
    		 0 2008-07-24 0

    SLATER EVE ELIZABETH

    • Director
    		 20,000 2007-06-01 0

    HARTMANN VICTOR A EVP, STRATEGIC & CORP. DEVLP.

    • Officer
    		 198,305 2007-05-03 0

    BRUM LYNNE H VP, STRATEGIC COMMUNICATIONS

    • Officer
    		 330,935 2006-05-08 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    BOZIC CARMEN - Officer EVP AND CMO

    		2023-09-21 16:15:36 -0400 2023-09-19 S 5,651 $351.00 d 51,905 direct yes 0.3262 0.3262 2 0.0 1

    BOZIC CARMEN - Officer EVP AND CMO

    		2023-09-07 16:29:38 -0400 2023-09-05 S 5,651 $352.66 d 57,556 direct yes 1.2156 1.7053 1.8569 5 0.0 1

    TATSIS OURANIA - Officer EVP, CHIEF REG. & QUALITY OFF.

    		2023-08-25 16:14:50 -0400 2023-08-23 S 2,500 $355.00 d 48,637 direct yes -0.0967 -0.9499 0.0 1 -0.9499 6

    SACHDEV AMIT - Officer EVP, CHIEF PATIENT OFFICER

    		2023-08-14 16:05:14 -0400 2023-08-10 S 10,031 $350.00 d 58,814 direct yes -1.8211 0.1773 0.2745 5 -1.8211 2

    TATSIS OURANIA - Officer EVP, CHIEF REG. & QUALITY OFF.

    		2023-08-14 16:08:52 -0400 2023-08-10 S 5,750 $345.79 d 51,137 direct yes -1.8211 0.1773 0.2745 5 -1.8211 2

    KEARNEY TERRENCE C - Director

    		2023-08-14 16:09:17 -0400 2023-08-10 M 10,000 $127.54 a 16,536 direct yes -1.8211 0.1773 0.2745 5 -1.8211 2

    KEARNEY TERRENCE C - Director

    		2023-08-14 16:09:17 -0400 2023-08-10 S 10,000 $350.00 d 6,536 direct yes -1.8211 0.1773 0.2745 5 -1.8211 2

    KEARNEY TERRENCE C - Director

    		2023-08-14 16:09:17 -0400 2023-08-10 M 10,000 d 10,000 direct yes

    ALTSHULER DAVID - Officer EVP, GLOBAL RESEARCH AND CSO

    		2023-08-11 16:05:13 -0400 2023-08-09 S 63 $345.51 d 32,038 direct yes 0.1174 0.3921 0.3921 6 -1.7059 3

    BHATIA SANGEETA N. - Director

    		2023-08-11 16:05:08 -0400 2023-08-09 S 242 $345.51 d 4,386 direct yes 0.1174 0.3921 0.3921 6 -1.7059 3

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-26 13:45:03 UTC 5.07 0.25 8000000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-26 13:15:03 UTC 5.07 0.25 8000000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-26 12:45:05 UTC 5.07 0.25 7900000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 22:15:04 UTC 5.07 0.25 8100000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 21:45:04 UTC 5.07 0.25 8100000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 21:15:04 UTC 5.07 0.25 8100000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 20:45:04 UTC 5.07 0.25 8100000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 20:15:04 UTC 5.07 0.25 8100000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 19:45:04 UTC 5.07 0.25 8100000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 19:15:04 UTC 5.07 0.25 8100000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 18:45:04 UTC 5.07 0.25 8100000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 18:15:03 UTC 5.07 0.25 8100000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 17:45:04 UTC 5.07 0.25 8100000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 17:15:03 UTC 5.07 0.25 8100000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 16:45:04 UTC 5.07 0.25 8100000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 16:15:03 UTC 5.07 0.25 8100000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 15:45:03 UTC 5.07 0.25 8100000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 15:15:04 UTC 5.07 0.25 8100000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 14:45:04 UTC 5.07 0.25 8100000
    VERTEX PHARMACEUTICALS INC VRTX 2023-09-25 14:15:04 UTC 5.07 0.25 8100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Absolute 500 Core Fund VRTX -44.0 shares, $-10469.8 2020-03-31 N-PORT
    FundVantage Trust- Gotham Enhanced 500 Plus Fund VRTX -29.0 shares, $-10205.39 2023-06-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments